Barclays lowered the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $59 and keeps an Equal Weight rating on the shares. The company Q3 update highlighted the CTX112 ASH abstract in B-cell malignancies with encouraging initial efficacy, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- CRISPR Therapeutics Advances with Solid Financials and Approvals
- Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)
- Crispr Therapeutics options imply 8.9% move in share price post-earnings
- CRSP Earnings this Week: How Will it Perform?
- Cathie Wood Trims Tesla Stake, Shifts Focus to This Lesser-Known Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
